Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide for Autism Spectrum Disorders with Inflammatory Markers
NCT00996931Phase 2Completed
- Sponsor
- Sutter Medical Foundation
- Start
- Feb 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lenalidomide in Autism Spectrum Disorder (ASD), sponsored by Sutter Medical Foundation. Started Feb 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00996931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996931.